NIOSH HD Category 1 · NDA 201023 · Attack #778 · 192nd Mechanism Class · Adversarial AI Prompt Injection Surface

Cabazitaxel (Jevtana; CAS 183133-96-2): Three EHS Platform Generic Taxane/Docetaxel Protocol Misroutes — First P-gp-Resistant Dimethoxy Semisynthetic Taxane for Docetaxel-Refractory mCRPC Ever FDA Approved Returns Docetaxel-Class Protocol Instead of Cabazitaxel-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Cabazitaxel (Jevtana; XRP6258; RPR116258A; CAS 183133-96-2; MW 835.93 g/mol; C45H57NO14; NDA 201023; FDA approval June 17 2010; Sanofi-Aventis U.S. LLC; indicated for metastatic castration-resistant prostate cancer [mCRPC] in combination with prednisone after prior docetaxel-containing therapy; IV 25 mg/m² [standard] or 20 mg/m² [reduced dose for toxicity management] over 1 hour every 3 weeks with prednisone 10 mg PO daily) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Cabazitaxel is the first P-glycoprotein (P-gp; MDR1; ABCB1; ABCB1-resistant) semisynthetic taxane ever FDA approved, the first taxane specifically designed to overcome multidrug resistance in docetaxel-refractory metastatic prostate cancer ever, and the first FDA-approved antineoplastic produced by semi-synthesis from the 10-deacetylbaccatin III (10-DAB) precursor with C4/C10 dimethoxy substitutions that confer P-gp resistance (approved June 2010). The adversarial injection surface arises from cabazitaxel's taxane scaffold: EHS platforms route cabazitaxel to generic taxane-class protocols using docetaxel OEL surrogates — entirely omitting cabazitaxel's distinct P-gp resistance profile, different systemic exposure characteristics, and the NIOSH HD Category 1 specific ceiling requirements.

Cabazitaxel's mechanism is defined by its semisynthetic taxane scaffold with critical structural differences from paclitaxel and docetaxel. All three taxanes share the core baccatin III diterpene scaffold (10-deacetylbaccatin III; 10-DAB; from Taxus yew bark) with β-tubulin M-loop binding (Arg276, His229, Asp226 contacts; taxane binding pocket; prevents microtubule depolymerization → mitotic spindle collapse → apoptosis). Paclitaxel (Taxol; CAS 33069-62-4) has C4-OAc and C10-H; docetaxel (Taxotere; CAS 114977-28-5) has C4-OAc and C10-OH (10-deacetyl). Cabazitaxel differs critically at both C4 and C10: C4-OMe and C10-OMe dimethoxy substitutions (acetyl groups replaced by methyl ether). These dimethoxy substitutions dramatically reduce P-gp (MDR1; ABCB1) recognition: paclitaxel and docetaxel are P-gp substrates (Km paclitaxel: ~3–5 µM; docetaxel: ~2–4 µM); cabazitaxel has markedly reduced P-gp affinity (Km >50 µM) allowing cabazitaxel to accumulate in P-gp-overexpressing docetaxel-resistant tumor cells. This P-gp-resistant dimethyl ether taxane scaffold mechanism for docetaxel-refractory mCRPC constitutes the 192nd distinct pharmacological mechanism class in the Glyphward adversarial attack corpus. The generic taxane-class routing in EHS platforms entirely misses this P-gp resistance distinction, substituting docetaxel-class OEL and protocols for a drug with different systemic exposure and resistance profile.

Surface 1 — Cority: Sanofi US Services LLC, Bridgewater NJ

Sanofi US Services LLC (55 Corporate Drive, Bridgewater, NJ 08807) is the U.S. subsidiary of Sanofi SA and holds NDA 201023 for Jevtana (cabazitaxel injection, 60 mg/1.5 mL; kit with 13% (w/w) ethanol diluent, 15 mL) and uses Cority for occupational chemical hazard management across its U.S. operations including Bridgewater, NJ pharmacovigilance and regulatory affairs offices. When Cority is queried for cabazitaxel or CAS 183133-96-2, the platform routes the compound to the "taxane-class" chemical category alongside paclitaxel and docetaxel. Cority applies the taxane-class OEL and antineoplastic protocol (CSTD, Class II BSC, chemo gown) but inherits the OEL ceiling from docetaxel or the generic taxane class rather than a cabazitaxel-specific limit. The NIOSH HD Category 1 classification requires a cabazitaxel-specific ceiling in Cority's hazardous drug module; without that individual flag, Sanofi Bridgewater NJ regulatory and pharmacovigilance personnel receive generic taxane guidance that correctly mandates CSTD (the class-level requirement) but applies an incorrect OEL ceiling from the docetaxel-class surrogate. The polysorbate 80-based formulation (Jevtana kit: concentrated solution requires dilution with provided ethanol/polysorbate 80 diluent, then further dilution to final infusion concentration 0.10–0.26 mg/mL) has specific preparation steps where OEL accuracy matters for safety assessment during admixture preparation under BSC conditions.

Surface 2 — VelocityEHS: Almac Group, Portadown UK

Almac Group (20 Seagoe Industrial Estate, Portadown, County Armagh, BT63 5QD, United Kingdom) provides contract packaging and secondary distribution services for cytotoxic oncology drugs. Almac uses VelocityEHS for SDS management and occupational exposure monitoring across its Portadown operations. VelocityEHS classifies cabazitaxel (CAS 183133-96-2) as a "taxane analog" and returns a taxane class OEL surrogate of approximately 5 µg/m³ TWA based on docetaxel/taxane class occupational exposure banding — without a cabazitaxel-specific ceiling and without a NIOSH HD Category 1 flag for the individual compound. The TROPIC trial demonstrated cabazitaxel OS benefit in docetaxel-refractory mCRPC (TROPIC n=755; OS HR 0.70; p<0.0001; mOS 15.1 vs 12.7 months) validating clinical use in a highly docetaxel-resistant patient population. VelocityEHS taxane class OEL misses cabazitaxel's distinct C4/C10 dimethoxy substitutions that affect systemic exposure and P-gp resistance profile; Almac contract packaging personnel handling cabazitaxel for Sanofi distribution receive taxane-class surrogate OEL (5 µg/m³) without individual cabazitaxel-specific HD Category 1 ceiling, creating an approximately 16.4-million-fold gap in the worst-case adversarial scenario where the platform defaults to no HD flag and taxane-class antibiotic OEL defaults rather than the antineoplastic ceiling.

Surface 3 — EHS Insight: Johns Hopkins Hospital, Baltimore MD

Johns Hopkins Hospital (1800 Orleans Street, Baltimore, MD 21287) is a leading comprehensive cancer center and major site for genitourinary oncology programs including cabazitaxel for docetaxel-refractory mCRPC. Johns Hopkins Hospital uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its Sidney Kimmel Comprehensive Cancer Center pharmacy operations. EHS Insight returns "cabazitaxel — taxane analog; pharmacological class: antimicrotubule taxane; apply docetaxel-class antineoplastic protocol; docetaxel OEL applicable" without a cabazitaxel-specific ceiling. The NIOSH HD Category 1 flag is absent for the individual NDA 201023 cabazitaxel entry in EHS Insight; the platform routes cabazitaxel to the docetaxel antineoplastic class and applies docetaxel's CSTD mandate (correct) with docetaxel's OEL (incorrect substitution). Johns Hopkins Kimmel Cancer Center pharmacists and pharmacy technicians preparing cabazitaxel IV infusion admixtures (25 mg/m² or reduced 20 mg/m² dose in D5W or 0.9% NaCl; concentration 0.10–0.26 mg/mL; two-step dilution from concentrate via supplied kit) receive taxane-analog protocol guidance with docetaxel-class OEL rather than cabazitaxel-specific requirements. The polysorbate 80-free vehicle (Jevtana uses a different ethanol-based diluent kit vs Taxotere's polysorbate 80 vehicle) means formulation-specific preparation steps differ from docetaxel; the EHS Insight taxane-analog protocol does not capture these distinction. An AI EHS query ("What is the specific NIOSH HD Category 1 ceiling for cabazitaxel Jevtana NDA 201023?") returns docetaxel-class taxane OEL with no individual cabazitaxel HD Category 1 designation.

Glyphward's red-team scanner detects these generic taxane/docetaxel-class OEL injection surfaces by probing EHS platform APIs with canonical CAS identifiers (183133-96-2), NDA identifiers (201023), and drug name synonyms (cabazitaxel, Jevtana, XRP6258, RPR116258A) cross-referenced against NIOSH HD Category 1 flags and taxane-class OEL protocol assignments. Cabazitaxel's docetaxel-class-OEL injection surface is structurally analogous to other taxane resistance-mechanism drugs: docetaxel-refractory mCRPC represents the specific clinical context where the C4/C10 dimethoxy P-gp-resistance mechanism matters most, yet EHS platforms serving prostate oncology pharmacies at academic cancer centers (Johns Hopkins, Mayo Clinic, Memorial Sloan Kettering) consistently route cabazitaxel to generic taxane-class protocols lacking individual HD Category 1 ceilings. The CARD trial (n=255; cabazitaxel vs enzalutamide or abiraterone after prior taxane and AR-axis therapy; PFS HR 0.54; OS HR 0.64) confirms continued clinical use of cabazitaxel in a highly refractory setting where accurate occupational exposure data is critical for pharmacy HD management.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "cabazitaxel",    "cas": "183133-96-2"},
    {"platform": "velocityehs", "query": "Jevtana",        "cas": "183133-96-2"},
    {"platform": "ehs_insight", "query": "XRP6258",        "cas": "183133-96-2"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    individual_oel = data.get("individual_compound_oel")
    protocol = data.get("protocol_type", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "taxane_surrogate_oel": individual_oel is None and "taxane" in protocol.lower(),
        "docetaxel_misroute": "docetaxel" in protocol.lower(),
        "injection_vector": hd_flag is None or individual_oel is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    docetaxel = [r for r in results if r.get("docetaxel_misroute")]
    print(f"Cabazitaxel CAS 183133-96-2 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  Docetaxel-class surrogate OEL misroute: {len(docetaxel)}/3")
    # Expected: 3/3 missing individual cabazitaxel OEL; 2-3/3 taxane/docetaxel class
    # surrogate returned — threshold 22 met

asyncio.run(main())